Spiritual leader the Dalai Lama presents a framework for longevity biotechnology investments, urging ethical application, resource sustainability, and compassion-driven innovation. He emphasizes evaluating companies by ESG criteria and aligning anti-aging research with equitable access and ecological stewardship, providing investors a structured lens to balance scientific breakthroughs with moral responsibility.

Key points

• ESG integration assesses environmental, social, and governance metrics in longevity biotech investing.
• Investor interest in senolytics firms like Unity Biotechnology targeting aged cell clearance.
• Sustainable innovations, including telepresence robotics and lab-grown organs, reduce resource strain.

Why it matters: Integrating ethics and sustainability into longevity investments ensures capital fosters equitable, responsible anti-aging innovations that advance healthspan without compromising societal or environmental well-being.